Perkins Capital Management Inc. Has $270,000 Stake in Apyx Medical Co. (NASDAQ:APYX)

Perkins Capital Management Inc. decreased its position in shares of Apyx Medical Co. (NASDAQ:APYX) by 7.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 217,500 shares of the company’s stock after selling 17,000 shares during the period. Perkins Capital Management Inc.’s holdings in Apyx Medical were worth $270,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Private Advisor Group LLC increased its holdings in shares of Apyx Medical by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock worth $400,000 after purchasing an additional 12,180 shares during the period. RPg Family Wealth Advisory LLC bought a new position in shares of Apyx Medical during the 2nd quarter worth about $101,000. Rathbones Group PLC increased its holdings in shares of Apyx Medical by 148.0% during the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after purchasing an additional 150,000 shares during the period. Commonwealth Equity Services LLC increased its holdings in shares of Apyx Medical by 2.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after purchasing an additional 14,481 shares during the period. Finally, Kingsview Wealth Management LLC increased its holdings in shares of Apyx Medical by 156.7% during the 1st quarter. Kingsview Wealth Management LLC now owns 31,028 shares of the company’s stock worth $42,000 after purchasing an additional 18,943 shares during the period. Institutional investors and hedge funds own 55.33% of the company’s stock.

Wall Street Analyst Weigh In

APYX has been the topic of several research reports. BTIG Research began coverage on shares of Apyx Medical in a report on Thursday, October 17th. They set a “neutral” rating on the stock. JMP Securities reissued a “market perform” rating on shares of Apyx Medical in a research report on Monday, September 16th. Finally, Craig Hallum raised shares of Apyx Medical to a “strong-buy” rating in a research report on Thursday, October 24th.

Apyx Medical Stock Performance

NASDAQ:APYX opened at $1.21 on Thursday. Apyx Medical Co. has a 12-month low of $0.97 and a 12-month high of $3.26. The company has a quick ratio of 4.45, a current ratio of 5.33 and a debt-to-equity ratio of 2.26. The firm has a market capitalization of $41.92 million, a PE ratio of -1.48 and a beta of 1.21. The firm has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.33.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The firm had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.67 million. Apyx Medical had a negative return on equity of 105.45% and a negative net margin of 57.86%. During the same period in the previous year, the business posted ($0.11) EPS. Research analysts anticipate that Apyx Medical Co. will post -0.7 earnings per share for the current fiscal year.

Apyx Medical Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.